Background
An innovative company in the dietary supplements sector has specialized in developing a unique probiotic known for its beneficial effects on gut health. After successfully completing all necessary clinical studies to validate its health benefits, the production of this dietary supplement began on a large scale in Italy in 2022.
However, in 2022, the company faced significant organizational challenges, notably the absence of a financial controller and the resignation of its office manager. These roles were crucial to supporting its growth and expansion and transitioning from research to production/marketing.
It was no longer just about developing a product and conducting clinical studies but about following numerous processes from manufacturing to sales, including marketing, packaging, and the logistics chain.
Additionally, funding sources were shifting: public grants were decreasing while the first sales were being recorded.